Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 1, 2012, Pages 66-76

  Subramanian, Venkateswaran ^a   Uchida, Haruhito A ^a,b   Ijaz, Talha ^a   Moorleghen, Jessica J ^a   Howatt, Deborah A ^a   Balakrishnan, Anju ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

aneurysm; angiotensin II; BDA 410; calpain

Indexed keywords

ANGIOTENSIN II; BDA 410; CALPAIN; CHOLESTEROL; CYSTEINE PROTEINASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROPHAGE ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; INHIBITION KINETICS; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ATHEROSCLEROSIS; BLOTTING, WESTERN; CALPAIN; CYSTEINE PROTEINASE INHIBITORS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; SULFONAMIDES;

EID: 84855342980     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318235d5ea     Document Type: Article

References (48)

1. Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell K, et al. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1996;16:963-970. (Pubitemid 26266894)
2. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577-1589. (Pubitemid 40615407)
3. -/- mice. Ann N Y Acad Sci. 1999;892:108-118.
4. Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg. 2002;39:110-230.
5. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612. (Pubitemid 30390311)
6. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121.
7. Saraff K, Babamusta F, Cassis LA, et al. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1621-1626. (Pubitemid 37108207)
8. Eagleton MJ, Ballard N, Lynch E, et al. Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during angiotensin II induced aneurysm formation. J Surg Res. 2006;135:345-351. (Pubitemid 44414882)
9. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-488. (Pubitemid 36337226)
10. Miyazaki M, Takai S, Jin D, et al. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006;112:668-676. (Pubitemid 44573489)
11. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation. 2009;120:973-982.
12. Schulte S, Sun J, Libby P, et al. Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. Am J Pathol. 2010;177:456-463.
13. Battaglia F, Trinchese F, Liu S, et al. Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci. 2003;20:357-362. (Pubitemid 38146994)
14. Saito K, Elce JS, Hamos JE, et al. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A. 1993;90:2628-2632. (Pubitemid 23113469)
15. Trinchese F, Fa' M, Liu S, et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest. 2008;118:2796-2807.
16. Tsubakimoto Y, Yamada H, Yokoi H, et al. Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol. 2009;29:1529-1536.
17. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000;26:163-175.
18. Ojima K, Kawabata Y, Nakao H, et al. Dynamic distribution of musclespecific calpain in mice has a key role in physical-stress adaptation and is impaired in muscular dystrophy. J Clin Invest. 2010;120:2672-2683.
19. Goll DE, Thompson VF, Li H, et al. The calpain system. Physiol Rev. 2003;83:731-801. (Pubitemid 36828925)
20. Smolock AR, Mishra G, Eguchi K, et al. Protein kinase C upregulates intercellular adhesion molecule-1 and leukocyte-endothelium interactions in hyperglycemia via activation of endothelial expressed calpain. Arterioscler Thromb Vasc Biol. 2011;31:289-296.
21. Sato K, Minegishi S, Takano J, et al. Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25. J Neurochem. 2011;117:504-515.
22. Carillo S, Pariat M, Steff AM, et al. Differential sensitivity of FOS and JUN family members to calpains. Oncogene. 1994;9:1679-1689. (Pubitemid 24163395)
23. Lin YC, Brown K, Siebenlist U. Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc Natl Acad Sci U S A. 1995;92:552-556.
24. Bevers MB, Neumar RW. Mechanistic role of calpains in postischemic neurodegeneration. J Cereb Blood Flow Metab. 2008;28:655-673. (Pubitemid 351432797)
25. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol. 2000;150:887-894. (Pubitemid 30663424)
26. McDonald MC, Mota-Filipe H, Paul A, et al. Calpain inhibitor I reduces the activation of nuclear factor-kappaB and organ injury/dysfunction in hemorrhagic shock. FASEB J. 2001;15:171-186. (Pubitemid 32061668)
27. Letavernier E, Perez J, Bellocq A, et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res. 2008;102:720-728. (Pubitemid 351457854)
28. Jiang L, Wang M, Zhang J, et al. Increased aortic calpain-1 activity mediates age-associated angiotensin II signaling of vascular smooth muscle cells. PLoS ONE. 2008;3:e2231.
29. Li X, Chen H, Jeong JJ, et al. BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. Mol Biochem Parasitol. 2007;155:26-32. (Pubitemid 47042214)
30. Daugherty A, Rateri D, Lu H, et al. Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. J Vis Exp. 2009;15:1291.
31. Daugherty A, Rateri DL, Lu H, et al. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. 2004;110:3849-3857. (Pubitemid 40023984)
32. Barisione C, Charnigo R, Howatt DA, et al. Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg. 2006;44:372-376. (Pubitemid 44142945)
33. Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol. 2003;209:293-309.
34. Daugherty A, Rateri DL. Development of experimental designs for atherosclerosis studies in mice. Methods. 2005;36:129-138. (Pubitemid 40726145)
35. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-434. (Pubitemid 38326134)
36. Sendobry SM, Cornicelli JA, Welch K, et al. Absence of T lymphocyte-derived cytokines fails to diminish macrophage 12/15-lipoxygenase expression in vivo. J Immunol. 1998;161:1477-1482. (Pubitemid 28380580)
37. Lu H, Boustany-Kari CM, Daugherty A, et al. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab. 2007;292:E1280-E1287. (Pubitemid 46684595)
38. Wang Y, Ait-Oufella H, Herbin O, et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432.
39. Cassis LA, Gupte M, Thayer S, et al. Angiotensin II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol. 2009;296:H1660- H1665.
40. Silence J, Lupu F, Collen D, et al. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440-1445. (Pubitemid 34219805)
41. Lemaitre V, O'Byrne TK, Borczuk AC, et al. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest. 2001;107:1227-1234. (Pubitemid 32494539)
42. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009;105:921-929.
43. Ouyang X, Le TH, Roncal C, et al. Th1 inflammatory response with altered expression of profibrotic and vasoactive mediators in AT1A and AT1B double-knockout mice. Am J Physiol Renal Physiol. 2005;289:F902-F910. (Pubitemid 41324211)
44. Deguchi JO, Aikawa E, Libby P, et al. Matrix metalloproteinase-13/ collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation. 2005;112:2708-2715. (Pubitemid 41532609)
45. Schneider F, Sukhova GK, Aikawa M, et al. Matrix metalloproteinase-14 deficiency in bone marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation. 2008;117:931-939. (Pubitemid 351272591)
46. Longo GM, Buda SJ, Fiotta N, et al. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery. 2005;137:457-462.
47. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649. (Pubitemid 30390315)
48. Johnson JL, Devel L, Czarny B, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2011;31:528-535.